Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease will webcast 2H and FY 2023 results, Wednesday March 6 at 9:30 am EET (8:30 CET). The presentation will be held by CEO Antti Vuolanto and CFO Tone Kvåle, followed by a Q&A session.

Herantis will release 2H and FY 2023 Report on March 6 at 8:00 am EET (7:00 CET). The report and presentation materials will be made available online at www.herantis.com.

Please use the following link to register for this event:
https://herantis.videosync.fi/fy-2023-report

After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event.

Following the webcast of the live call, a recording will be available on Herantis Pharma’s website: https://herantis.com/news-events/video-presentations/

For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com